Antibody Drug Conjugate ELISA
Krishgen’s range of KRIBIOLSA Antibody Drug Conjugates (ADCs) ELISA kits are meticulously designed to facilitate precise and sensitive detection and quantification of ADCs – a groundbreaking class of therapeutic agents at the forefront of targeted cancer therapy.
Antibody Drug Conjugates (ADCs) represent a revolutionary approach in oncology, merging the exceptional specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic drugs. This unique combination enables highly targeted delivery of cytotoxic payloads to cancer cells while minimizing off-target toxicity, thereby enhancing therapeutic efficacy, and diminishing systemic side effects. ADC ELISA kits provide researchers and pharmaceutical developers with the accurate and specific tools for comprehensive analysis and optimization of these promising therapeutic agents.
Harnessing optimized and validated immunoassay techniques, Krishgen ELISA ensure accurate measurement of ADC concentrations in diverse biological matrices. By precisely quantifying ADC levels, researchers can gain insights into their stability, bioactivity, and pharmacokinetic profiles, empowering them to fine-tune drug formulations, evaluate novel candidates, and optimize treatment strategies.
With an increasing number of ADC-based therapies advancing through clinical trials, robust and reliable assays are indispensable for assessing the pharmacokinetics and pharmacodynamics of these innovative drugs. Our ELISA kits serve as a critical tool for monitoring ADC concentrations in patient samples, evaluating drug exposure, and elucidating the correlation between ADC levels and clinical outcomes. Antibody Drug Conjugates also need meticulous investigation into the biodistribution, internalization, and release kinetics, mechanism of action and optimizing therapeutic potential.
Krishgen’s highly specific assays are developed for pharmaco-kinetic analysis and therapeutic drug monitoring, offering reproducible and reliable results.
- Produced in an ISO 13485 certified facility
- Validated as per international guidelines for bioassay validation
- Consistent lot-to-lot with intra- and inter- assay precision <15%
- Developed in a sandwich ELISA for higher specificity using monoclonal antibodies
- Biotinylated detection antibodies offer higher sensitivity, and lyophilized standards / calibrators offer longer stability
- Recovery: 85 – 120%
World’s Largest range of ADC ELISA
Krishgen offers 25+ immunoassays for the quantification of various antibody drug conjugates, the largest such range of ELISA worldwide. Can’t find your target ADC ELISA? Speak to our services team for a custom development.
Related Research Areas
Related Blogs
Content coming soon.
Antibody Drug Conjugate ELISA
Antibody-drug conjugates (ADCs) represent a class of innovative therapeutics that harness the power of monoclonal antibodies to deliver potent cytotoxic drugs directly to target cells. This targeted drug delivery approach offers several advantages over traditional chemotherapy, including improved efficacy, reduced systemic toxicity, and enhanced selectivity. ADCs are part of a broader movement towards personalized medicine which seeks to tailor medical care to an individual patient.
ADCs are composed of three key components: a monoclonal antibody, a linker, and a cytotoxic drug. The monoclonal antibody specifically recognizes and binds to a target antigen that is overexpressed on the surface of tumor cells. This antigen-antibody interaction serves as the guiding mechanism for the delivery of the attached cytotoxic drug directly to the cancer cells.
Mechanism of Action: Once the ADC binds to the target antigen, it is internalized into the cancer cell via receptor-mediated endocytosis. Within the cancer cell, the linker is designed to be selectively cleaved, releasing the cytotoxic drug into the cellular environment. The released drug then exerts its cytotoxic effects, inducing cell death and inhibiting tumor growth.
Advantages of ADCs: ADCs offer several advantages over conventional chemotherapy approaches. By leveraging the specificity of monoclonal antibodies, ADCs can selectively target cancer cells while minimizing damage to healthy tissues, thereby reducing systemic toxicity. This targeted approach helps improve patient outcomes and enhance the therapeutic index of the drugs. Moreover, ADCs have the potential to overcome drug resistance mechanisms that often arise during chemotherapy. The combination of antibody-based targeting and potent cytotoxic drugs allows for enhanced tumor cell killing and increased potency against previously resistant tumors.
In Clinical Use: Antibody-drug conjugates (ADCs) are a class of targeted therapy for cancer treatment with potential applications beyond oncology. As of 2021, over 80 ADCs are in clinical development with 11 US FDA-approved ADCs on the market. ADCs are being used in various therapeutic areas, including breast cancer, lymphomas, leukemias, prostate cancer, and lung cancer. Several ADCs are in clinical trials for the treatment of other diseases, such as multiple sclerosis, Crohn’s disease, and rheumatoid arthritis. ADCs are a rapidly expanding field, with new research exploring their potential in areas such as imaging, neurodegenerative disorders, and infectious diseases.
If you are unable to locate your desired ELISA kit on our website, or have a technical query, please drop us a message and our team will come back to you with availability. If we do not have it available, we will suggest a feasible custom development option.
Require a Custom Assay?
Krishgen can develop and manufacture to your specific requirements.
Whether you require a change in the assay range or sensitivity, want an assay validated for a specific matrix or even want an novel immunoassay developed, the Krishgen team can support you. Get a free technical consultation to learn about the feasibility and timeline of your new assay.